Imunon (IMNN) Change in Accured Expenses (2010 - 2026)

Imunon (IMNN) has 17 years of Change in Accured Expenses data on file, last reported at -$567158.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 160.53% year-over-year to -$567158.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (down 446.18% YoY) and the FY2025 annual result came in at -$521121.0, up 82.96% from the prior year.
• Change in Accured Expenses eased to -$567158.0 in Q1 2026, from $320230.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q4 2023 to a low of -$2.7 million in Q1 2024.
• A 5-year average of -$298002.4 and a median of -$96063.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2127.57% in 2023, down 851.68% in 2023.
• Tracing IMNN's Change in Accured Expenses over 5 years: stood at -$96063.0 in 2022, then soared by 2127.57% to $1.9 million in 2023, then sank by 137.29% to -$726403.0 in 2024, then jumped by 144.08% to $320230.0 in 2025, then tumbled by 277.11% to -$567158.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$567158.0 (Q1 2026), $320230.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.